Literature DB >> 458558

Clinical pharmacokinetics of procainamide infusions in relation to acetylator phenotype.

J J Lima, D R Conti, A L Goldfarb, W J Tilstone, L H Golden, W J Jusko.   

Abstract

The pharmacokinetics of procainamide was determined in 21 lidocaine-resistant patients who received the drug according to a pharmacokinetically designed double-infusion technique. Thirteen patients were phenotyped as slow acetylators, seven as fast, and one as intermediate. The total body clearances (ClT) of PA in slow and fast acetylators were 22.6 and 34.8 liters/hr, respectively. The fraction of PA cleared by the formation of NAPA in the corresponding acetylator group was 0.2 and 0.4. Renal impairment affected the pharmacokinetics of PA more profoundly as the ClT's of PA in patients with and without renal impairment were 17.9 and 31.2 liters/hr, respectively. None of the calculated volumes of distribution was affected by acetylator phenotype or renal impairment. These data identify the contribution of at least two of the major factors accounting for variability in PA disposition in patients undergoing therapy.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 458558     DOI: 10.1007/bf01059442

Source DB:  PubMed          Journal:  J Pharmacokinet Biopharm        ISSN: 0090-466X


  21 in total

1.  The pharmacokinetics of procainamide in normal subjects using a specific gas chromatographic assay.

Authors:  K J Simons; R H Levy; R E Cutler; G T Christopher; A Lindner
Journal:  Res Commun Chem Pathol Pharmacol       Date:  1975-06

2.  Elimination rate of N-acetylprocainamide after a single intravenous dose of procainamide hydrochloride in man.

Authors:  C Graffner
Journal:  J Pharmacokinet Biopharm       Date:  1975-04

3.  Pharmacokinetics in man of the N-acetylated metabolite of procainamide.

Authors:  J M Strong; J S Dutcher; W K Lee; A J Atkinson
Journal:  J Pharmacokinet Biopharm       Date:  1975-08

4.  Metabolism of procainamide in normal and cardiac subjects.

Authors:  E G Giardina; J Dreyfuss; J T Bigger; J M Shaw; E C Schreiber
Journal:  Clin Pharmacol Ther       Date:  1976-03       Impact factor: 6.875

5.  Procainamide and N-acetylprocainamide kinetics investigated simultaneously with stable isotope methodology.

Authors:  J S Dutcher; J M Strong; S V Lucas; W K Lee; A J Atkinson
Journal:  Clin Pharmacol Ther       Date:  1977-10       Impact factor: 6.875

6.  Antiarrhythmic efficacy of N-acetylprocainamide in patients with premature ventricular contractions.

Authors:  W K Lee; J M Strong; R F Kehoe; J S Dutcher; A J Atkinson
Journal:  Clin Pharmacol Ther       Date:  1976-05       Impact factor: 6.875

7.  Salivary excretion and pharmacokinetics of sulfapyridine after sulfasalazine.

Authors:  T R Bates; H P Blumenthal; H J Pieniaszek
Journal:  Clin Pharmacol Ther       Date:  1977-12       Impact factor: 6.875

8.  Pharmacokinetics of procainamide.

Authors:  H S Weily; E Genton
Journal:  Arch Intern Med       Date:  1972-09

9.  Procainamide dosage schedules, plasma concentrations, and clinical effects.

Authors:  J Koch-Weser; S W Klein
Journal:  JAMA       Date:  1971-03-01       Impact factor: 56.272

10.  Pharmacokinetic approach to intravenous procainamide therapy.

Authors:  J J Lima; D R Conti; A L Goldfarb; L H Golden; W J Jusko
Journal:  Eur J Clin Pharmacol       Date:  1978-06-19       Impact factor: 2.953

View more
  8 in total

1.  The role of metabolites in bioequivalency assessment. I. Linear pharmacokinetics without first-pass effect.

Authors:  M L Chen; A J Jackson
Journal:  Pharm Res       Date:  1991-01       Impact factor: 4.200

Review 2.  Drug metabolites in renal failure: pharmacokinetic and clinical implications.

Authors:  R K Verbeeck; R A Branch; G R Wilkinson
Journal:  Clin Pharmacokinet       Date:  1981 Sep-Oct       Impact factor: 6.447

3.  Optimal sampling times for pharmacokinetic experiments.

Authors:  D Z D'Argenio
Journal:  J Pharmacokinet Biopharm       Date:  1981-12

Review 4.  Use of in vitro and in vivo data to estimate the likelihood of metabolic pharmacokinetic interactions.

Authors:  R J Bertz; G R Granneman
Journal:  Clin Pharmacokinet       Date:  1997-03       Impact factor: 6.447

Review 5.  Practical optimisation of antiarrhythmic drug therapy using pharmacokinetic principles.

Authors:  J L Bauman; M D Schoen; T J Hoon
Journal:  Clin Pharmacokinet       Date:  1991-02       Impact factor: 6.447

6.  Population pharmacokinetics of procainamide from routine clinical data.

Authors:  T H Grasela; L B Sheiner
Journal:  Clin Pharmacokinet       Date:  1984 Nov-Dec       Impact factor: 6.447

Review 7.  Clinical pharmacokinetics of N-acetylprocainamide.

Authors:  S J Connolly; R E Kates
Journal:  Clin Pharmacokinet       Date:  1982 May-Jun       Impact factor: 6.447

Review 8.  Genetically determined variability in acetylation and oxidation. Therapeutic implications.

Authors:  D W Clark
Journal:  Drugs       Date:  1985-04       Impact factor: 9.546

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.